Clinical Trial Update: Study of Valortim® (MDX-1303) and Its Selected Formulation Components Percutaneous Use [Phase 1]

View source ↗

Summary

Phase 1 study updates Valortim (MDX-1303) and selected formulation components for percutaneous use. The trial status is completed and pertains to allergic react…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Reactions

Drugs mentioned

• Valortim (MDX-1303)

Snippet

Sponsor: PharmAthene, Inc. | Conditions: Allergic Reactions | Phase 1 | Status: COMPLETED